[1] Samii A, Al E. Parkinson's disease. Lancet 2004;363(9423):1783-93.
[2] Kordower JH, C Warren O, Dodiya HB, Yaping C, Beach TG, Adler CH, Halliday GM, Bartus RT. Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain 2013;136(8):2419-31.
[3] Antonini A. Levodopa in the treatment of Parkinson’s disease: an old drug still going strong. Clin Interv Aging 2010;5:229-38.
[4] Sgroi S, Kaelin-Lang A, Capper-Loup C. Spontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats. Front Behav Neurosci 2014;8(4):331.
[5] Encarnacion E, Hauser R. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol 2008;60(2):57-66.
[6] Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots – A concise summary. Vascul Pharmacol. 2019;113:1-8.
[7] Zhang C, Wang Y, Wang D, Zhang J, Zhang F. NSAID Exposure and Risk of Alzheimer's Disease: An Updated Meta-Analysis From Cohort Studies. Front Aging Neurosci 2018;10:83.
[8] Ayyadevara S, Balasubramaniam M, Kakraba S, Alla R, Mehta JL, Shmookler Reis RJ. Aspirin-Mediated acetylation protects against multiple neurodegenerative pathologies by impeding protein aggregation. Antioxid Redox Signal 2017;27(17):1383-96.
[9] Maharaj H, Maharaj DS, Daya S. Acetylsalicylic acid and acetaminophen protect against MPP+-induced mitochondrial damage and superoxide anion generation. Life Sci 2006;78(21):2438-43.
[10] Jiao M, Hai Z, Lei-Ping Y, Pei-Hua S, Guo-Zhang J, Xuechu Z. L-stepholidine reduced L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neurobiol Aging 2010;31(6):926-36.
[11] Khuwaja G, Khan MM, Ishrat T, Ahmad A, Raza SS, Ashafaq M, Javed H, Khan MB, Khan A, Vaibhav K, Safhi MM, Islam F. Neuroprotective effects of curcumin on 6-hydroxydopamine-induced Parkinsonism in rats: Behavioral, neurochemical and immunohistochemical studies. Brain Res 2011;1368(1):254-63.
[12] Ostock CY, Hallmark J, Palumbo N, Bhide N, Conti M, George JA, Bishop C. Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus. Neuropharmacology 2015;95:215-25.
[13] Lu DS, Chen C, Zheng YX, Li DD, Wang GQ, Liu J, Shi J, Zhang F. Combination treatment of icariin and L-DOPA against 6-OHDA-Lesioned dopamine neurotoxicity. Front Mol Neurosci 2018;11:155-.
[14] Xie C, Wang WW, Zhang S, Yuan ML, Che JY, Gan J, Song L, Yuan WE, Liu ZG. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats. Sci Rep 2014;4:7506.
[15] David L, Ostock CY, Jaunarajs KL, Eskow, Dupre KB, Barnum CJ, Nirmal B, Bishop C. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. J Pharmacol Exp Ther 2011;337(3):755-65.
[16] Alam S. The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy. Pharmacol Biochem Behav 2007;87(3):306-14.
[17] Chotibut T, Meadows S, Kasanga EA, McInnis T, Cantu MA, Bishop C, Salvatore MF. Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model. Mov Disord 2017;32(11):1547-56.
[18] Greene JG, Dingledine R, Greenamyre JT. Neuron-selective changes in RNA transcripts related to energy metabolism in toxic models of parkinsonism in rodents. Neurobiol Dis 2010;38(3):476-81.
[19] Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16(3):448–58.
[20] Grandas F, Galiano ML, Tabernero C. Risk factors for levodopa-induced dyskinesias in Parkinson's disease. J Neurol 1999;246(12):1127-33.
[21] Stocchi F, Tagliati M, Olanow CW. Treatment of levodopa-induced motor complications. Mov Disord 2010;23(S3):S599-S612.
[22] Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna) 2018;125(8):1237-50.
[23] Pilleri M, Antonini A. Therapeutic strategies to prevent and manage dyskinesias in Parkinson’s disease. Expert Opin Drug Saf 2014;14(2):281-94.
[24] Aubin N, Curet O, Deffois A, Carter C. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice.J Neurochem 1998;71:1635-42.
[25] Carrasco E, Werner P. Selective destruction of dopaminergic neurons by low concentrations of 6-OHDA and MPP+: protection by acetylsalicylic acid aspirin. Parkinsonism Relat Disord 2002;8(6):407-11.
[26] Di Matteo V, Pierucci M, Di Giovanni G, Di Santo A, Poggi A, Benigno A, Esposito E. Aspirin protects striatal dopaminergic neurons from neurotoxin-induced degeneration: an in vivo microdialysis study. Brain Res2006;1095(1):167-77.
[27] Huh E, Choi JG, Sim Y, Oh MS. An integrative approach to treat parkinson's disease: ukgansan complements L-Dopa by ameliorating dopaminergic neuronal damage and L-Dopa-induced dyskinesia in mice. Front Aging Neurosci 2018;10:431.
[28] Carta AR, Mulas G, Bortolanza M, Duarte T, Pillai E, Fisone G, Vozari RR, Del-Bel E. L-DOPA-induced dyskinesia and neuroinflammation: do microglia and astrocytes play a role? Eur J Neurosci 2016;45(1):73-91.
[29] Aldakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in parkinson disease. Neurotherapeutics 2014;11(1):6-23.
[30] Speck AE, Schamne MG, Aguiar AS, Cunha RA, Rui DP. Treadmill exercise attenuates L-DOPA-induced dyskinesia and increases striatal levels of glial cell-derived neurotrophic factor (GDNF) in hemiparkinsonian mice. Mol Neurobiol 2018;56:2944-2951.
[31] Li W-Y, Li F-M, Zhou Y-F, Wen Z-M, Ma J, Ya K, Qian ZM. Aspirin down regulates hepcidin by inhibiting NF-κB and IL6/JAK2/STAT3 pathways in BV-2 microglial cells treated with lipopolysaccharide. Int J Mol Sci 2016;17(12):1921.
[32] Lindenbach D, Ostock CY, Eskow Jaunarajs KL, Dupre KB, Barnum CJ, Bhide N, Bishop C. Behavioral and cellular modulation of L-DOPA-induced dyskinesia by beta-adrenoceptor blockade in the 6-hydroxydopamine-lesioned rat. J Pharmacol Exp Ther 2011;337(3):755-65.